Bellicum, Leiden University Medical Center deal

Bellicum and the center partnered to discover and validate high-affinity T cell receptor (TCR) candidates to treat cancer. The biotech, which will provide its CaspaCIDe switch technology, will have exclusive, worldwide rights to compounds discovered under the deal. Bellicum also will provide three years of research funding to the medical center. Bellicum’s CaspaCIDe technology consists of chemically-induced dimerization domain coupled to the signaling domain of caspase-9 ( CASP9; MCH6) gene. ...